Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Safety and Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both genders aged from 18 to 60 years inclusively.~* Patients who visited a doctor during the increase of seasonal incidence within 24 hours after the onset of acute respiratory infection of the upper respiratory tract.~* Body temperature ≥37,8°C at the moment of examination by the doctor.~* Presence of two or more moderate severity symptoms or three or more mild severity symptoms according to the Common Cold Questionnaire (CCQ).~* The possibility to start therapy within 24 hours from the onset of the first symptoms of acute respiratory infection of the upper respiratory tract.~* The use of contraceptive methods by the patients of both the sexes during the study and within 30 days after completion of participation in the study.~* Availability of signed patient information sheet (Informed Consent form) for participation in the clinical trial.~Exclusion Criteria:~* Suspected invasive bacterial infection or the presence of a severe disease requiring use of antibacterial drugs (including sulfanilamides).~* Suspected initial manifestations of diseases that have symptoms similar to acute URTI (other infectious diseases, flu-like symptoms at the onset of systemic connective tissue disorders, hematologic neoplasms and other pathologies).~* Exacerbated or decompensated chronic diseases affecting a patient's ability to participate in the clinical trial.~* Oncological diseases.~* Medical history of polyvalent allergy.~* Allergy/intolerance to any of the components of medications used in the treatment.~* Impaired glucose tolerance, diabetes mellitus type 1 and 2.~* Hereditary fructose intolerance (due to the presence of maltitol in the study drug).~* Use of any medicine listed in the section Prohibited concomitant treatment within 30 days preceding the inclusion in this study.~* Pregnancy, breastfeeding.~* Consumption of narcotics, alcohol \> 2 alcohol units per day.~* Patients with mental disorders.~* Patients who, from the investigator's point of view, will fail to comply with the observation requirements of the trial or with the regimen of the study drugs.~* Participation in other clinical studies within 3 months prior to enrollment in the current trial.~* Other factors, which hinder the patient's participation in the trial (for example, planned trips or business trips).~* Patients are related to the research staff of the clinical trial site who are directly involved in the trial or are the immediate family member of the researcher. The immediate family members include husband/wife, parents, children or brothers (or sisters), regardless of whether they are natural or adopted.~* Patients employed with MATERIA MEDICA HOLDING (i.e., the company's employee, a part-time employee under contract, or appointed official in charge of the trial, or their immediate family).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Ergoferon (5 ml 3 times a day) (Type: EXPERIMENTAL): Oral use. Dose per administration: 1 dosing spoon (5ml) without food. For best effect, the solution should be held in the mouth before swallowing.~Dosing scheme. One dose every 30 minutes for the first 2 hours, followed by three more doses spaced regularly during the rest of the day. From day 2 to 5: 1 spoon taken 3 times daily.
- Placebo (5 ml 3 times a day) (Type: PLACEBO_COMPARATOR): Oral use. Placebo using Ergoferon scheme.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete